Literature DB >> 23551098

Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunity.

Klaus Okkenhaug1.   

Abstract

Mammalian cells can express up to four different class I phosphatidylinositide 3-kinase (PI3K) isoforms, each of which is engaged by tyrosine kinases or G protein-coupled receptors (GPCRs) to generate the second messenger signaling molecule PtdIns(3,4,5)P₃ (PIP₃). The p110α and p110β isoforms are relatively widely expressed, whereas p110γ and p110δ are more highly expressed in cells of the immune system than in other cell types. Nevertheless, each of the four class I PI3Ks have been shown to participate in the orchestration of the signaling events that lead to immune cell development and control of gene expression, skewing toward individual cell lineage subsets and proliferation.
© 2013 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23551098      PMCID: PMC4523620          DOI: 10.1111/nyas.12027

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

1.  CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer.

Authors:  Fabien Garçon; Daniel T Patton; Juliet L Emery; Emilio Hirsch; Robert Rottapel; Takehiko Sasaki; Klaus Okkenhaug
Journal:  Blood       Date:  2007-11-15       Impact factor: 22.113

2.  Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction.

Authors:  Julia Rolf; Sarah E Bell; Dorottya Kovesdi; Michelle L Janas; Dalya R Soond; Louise M C Webb; Sara Santinelli; Ted Saunders; Barbara Hebeis; Nigel Killeen; Klaus Okkenhaug; Martin Turner
Journal:  J Immunol       Date:  2010-09-08       Impact factor: 5.422

3.  The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.

Authors:  Faruk Ramadani; Daniel J Bolland; Fabien Garcon; Juliet L Emery; Bart Vanhaesebroeck; Anne E Corcoran; Klaus Okkenhaug
Journal:  Sci Signal       Date:  2010-08-10       Impact factor: 8.192

4.  PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.

Authors:  Dalya R Soond; Elisa Bjørgo; Kristine Moltu; Verity Q Dale; Daniel T Patton; Knut Martin Torgersen; Fiona Galleway; Breda Twomey; Jonathan Clark; J S Hill Gaston; Kjetil Taskén; Peter Bunyard; Klaus Okkenhaug
Journal:  Blood       Date:  2010-01-15       Impact factor: 22.113

5.  Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing.

Authors:  Karin Reif; Klaus Okkenhaug; Takehiko Sasaki; Joseph M Penninger; Bart Vanhaesebroeck; Jason G Cyster
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

6.  Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.

Authors:  Klaus Okkenhaug; Antonio Bilancio; Géraldine Farjot; Helen Priddle; Sara Sancho; Emma Peskett; Wayne Pearce; Stephen E Meek; Ashreena Salpekar; Michael D Waterfield; Andrew J H Smith; Bart Vanhaesebroeck
Journal:  Science       Date:  2002-07-18       Impact factor: 47.728

7.  Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils.

Authors:  Alison M Condliffe; Keith Davidson; Karen E Anderson; Chris D Ellson; Tom Crabbe; Klaus Okkenhaug; Bart Vanhaesebroeck; Martin Turner; Louise Webb; Matthias P Wymann; Emilio Hirsch; Thomas Ruckle; Montserrat Camps; Christian Rommel; Shaun P Jackson; Edwin R Chilvers; Len R Stephens; Phillip T Hawkins
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

8.  PI3Kβ plays a critical role in neutrophil activation by immune complexes.

Authors:  Suhasini Kulkarni; Cassian Sitaru; Zoltan Jakus; Karen E Anderson; George Damoulakis; Keith Davidson; Misa Hirose; Jatinder Juss; David Oxley; Tamara A M Chessa; Faruk Ramadani; Herve Guillou; Anne Segonds-Pichon; Anja Fritsch; Gavin E Jarvis; Klaus Okkenhaug; Ralf Ludwig; Detlef Zillikens; Attila Mocsai; Bart Vanhaesebroeck; Len R Stephens; Phillip T Hawkins
Journal:  Sci Signal       Date:  2011-04-12       Impact factor: 8.192

9.  The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells.

Authors:  Klaus Okkenhaug; Daniel T Patton; Antonio Bilancio; Fabien Garçon; Wendy C Rowan; Bart Vanhaesebroeck
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

10.  Thymic development beyond beta-selection requires phosphatidylinositol 3-kinase activation by CXCR4.

Authors:  Michelle L Janas; Gabriele Varano; Kristjan Gudmundsson; Mamiko Noda; Takashi Nagasawa; Martin Turner
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

  10 in total
  11 in total

1.  Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways.

Authors:  N A Zwang; R Zhang; S Germana; M Y Fan; W D Hastings; A Cao; L A Turka
Journal:  Am J Transplant       Date:  2016-05-23       Impact factor: 8.086

Review 2.  MicroRNA regulation of B cell receptor signaling.

Authors:  Timothy C Borbet; Marcus J Hines; Sergei B Koralov
Journal:  Immunol Rev       Date:  2021-09-14       Impact factor: 12.988

3.  PI3K Signaling in B Cell and T Cell Biology.

Authors:  Klaus Okkenhaug; Martin Turner; Michael R Gold
Journal:  Front Immunol       Date:  2014-11-03       Impact factor: 7.561

Review 4.  PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).

Authors:  Klaus Okkenhaug; Jan A Burger
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

5.  PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells.

Authors:  Jacob S Bowers; Kinga Majchrzak; Michelle H Nelson; Bulent Arman Aksoy; Megan M Wyatt; Aubrey S Smith; Stefanie R Bailey; Lillian R Neal; Jeffrey E Hammerbacher; Chrystal M Paulos
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561

6.  First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.

Authors:  Eric Helmer; Mark Watling; Emma Jones; Dominique Tytgat; Mark Jones; Rodger Allen; Andrew Payne; Annelize Koch; Eugene Healy
Journal:  Eur J Clin Pharmacol       Date:  2017-02-04       Impact factor: 2.953

Review 7.  Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Sarah Sammons; Noah S Kornblum; Kimberly L Blackwell
Journal:  Target Oncol       Date:  2019-02       Impact factor: 4.493

8.  Extracellular Vesicles Mediate Mesenchymal Stromal Cell-Dependent Regulation of B Cell PI3K-AKT Signaling Pathway and Actin Cytoskeleton.

Authors:  Annalisa Adamo; Jessica Brandi; Simone Caligola; Pietro Delfino; Riccardo Bazzoni; Roberta Carusone; Daniela Cecconi; Rosalba Giugno; Marcello Manfredi; Elisa Robotti; Emilio Marengo; Giulio Bassi; Paul Takam Kamga; Giada Dal Collo; Alessandro Gatti; Angela Mercuri; Maddalena Arigoni; Martina Olivero; Raffaele A Calogero; Mauro Krampera
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

9.  PI3Kδ Regulates the Magnitude of CD8+ T Cell Responses after Challenge with Listeria monocytogenes.

Authors:  Verity Q Pearce; Hicham Bouabe; Amy R MacQueen; Valentina Carbonaro; Klaus Okkenhaug
Journal:  J Immunol       Date:  2015-08-26       Impact factor: 5.422

Review 10.  The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.

Authors:  Benjamin L Lampson; Jennifer R Brown
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-27       Impact factor: 2.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.